Biomarkers-based Personalized Follow-up in Chronic Heart Failure Improves Patient’s Outcomes and Reduces Care Associate Cost

Antonio Leon Justel (antonio.leonj.sspa@juntadeandalucia.es)
Complejo Hospitalario Virgen de la Macarena: Hospital Universitario Virgen Macarena
https://orcid.org/0000-0002-2219-7129

Jose Ignacio Morgado Garcia-Polavieja
Specialty Hospital Juan Ramon Jimenez: Hospital Juan Ramon Jimenez

Ana Isabel Alvarez Rios
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Francisco Jose Caro Fernandez
Specialty Hospital Juan Ramon Jimenez: Hospital Juan Ramon Jimenez

Pedro Agustin Pajaro Merino
Specialty Hospital Juan Ramon Jimenez: Hospital Juan Ramon Jimenez

Elena Galvez Rios
Specialty Hospital Juan Ramon Jimenez: Hospital Juan Ramon Jimenez

Ignacio Vazquez Rico
Specialty Hospital Juan Ramon Jimenez: Hospital Juan Ramon Jimenez

Jose Francisco Diaz Fernandez
Specialty Hospital Juan Ramon Jimenez: Hospital Juan Ramon Jimenez

Research

Keywords: Heart failure, Personalized medicine, Patient value, Patient outcomes, Budget impact

DOI: https://doi.org/10.21203/rs.3.rs-117453/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

BACKGROUND

Heart failure (HF) is a major and growing medical and economic problem, with high prevalence and incidence rates worldwide. Cardiac Biomarker is emerging as a novel tool for improving management of patients with HF.

METHODS

This is a real-world, before-and after-intervention trial, that assesses the impact of a personalized follow-up procedure for HF on patient's outcomes and care associated cost, based on a clinical model of risk stratification and personalized management according to that risk. A total of 192 patients were enrolled and studied before and after an intervention. The primary objective was the rate of readmissions, due to a HF event, post-intervention compared to pre-intervention. Secondary outcomes compared the rate of ED visits and the number of patients who had reduced NYHA score pre and post-intervention. A cost- analysis was also performed on these data.

RESULTS

Admission rates significantly decreased by 41% after the intervention (total length of stay was reduced by 55%). The rate of ED visits was reduced by 55%. Thirty-one percent of patients had an improved functional class score after the intervention, whereas only 7.8% got worse. The overall cost saving associated with the intervention was €139,717.65 for the whole group over 1 year.

CONCLUSIONS

A personalized follow-up of HF patients led to important outcome benefits and resulted in cost savings, mainly due to the reduction of patient hospitalization readmissions and a significant reduction of care- associated costs, suggesting that greater attention should be given to this high-risk cohort to minimize the risk of hospitalization readmissions.

Introduction

Heart failure (HF) is a major and growing medical and economic problem, with high prevalence and incidence rates worldwide [1,2]. It has been estimated that 0.5–2.2% of the population of industrialized countries suffer from HF, affecting more than 26 million people around the world, and HF is a leading cause of hospitalization [3,4]. The economic burden of HF is estimated at US$108 billion per annum [5]. Patients with HF who have been hospitalized once have elevated hospital readmission rates, with nearly one in four patients being readmitted within 30 days of discharge, leading to increased care costs and poor outcomes [6].

Whilst improvements in therapy have enabled patients to live with HF for longer [7], optimizing management of HF remains a challenge and still today readmission rates following HF hospitalization remain high [8]. The association between readmissions, poor outcomes and rising costs is greatest in the first year after discharge, suggesting a need for interventions that increase surveillance in the early post-discharge period [9]. Personalized management of HF patients could address some of the challenges, and cardiac biomarkers are
emerging as a novel tool in for improve HF care [10]. Major Guidelines give recommendations for the use of biomarkers for assessing the risk of readmission and identifying unaffected patients at risk for incident HF, but provide very little recommendation about the optimal methods and whether biomarkers can or should be used for guiding chronic heart failure with reduced-ejection-fraction (HFrEF) follow-up and monitoring [11,12].

On the other hand, people affected by HF experience different physical and mental complications due to the chronic and prolonged disease course which have a serious and negative impact on patient's health-related quality of life (QoL). Poorer health-related QoL correlates with increased hospitalization times and mortality rates as well as higher costs imposed on health systems, families, and patients [13]. QoL in heart failure patients is a key objective of management. Assessment of health-related QoL is recommended. However, there is a lack of clarity on the best method. Despite the use of validated health-related QoL assessments in clinical trials, their use in routine practice is yet to be widely adopted [14]. Conversely, functional assessment using New York Heart Association (NYHA) classification is standard procedure in the monitoring of heart failure patients. In accordance with that, the focus should be the concept of using health-related QoL as endpoint for therapeutic intervention in chronic diseases such as HF [15].

Our objective was to study and validate a new, real-world clinical practice approach for HF personalized follow-up based on cardiac biomarkers compared with regular care in our clinical setting. Secondly, evaluate the impact on reduction of hospitalization readmission rates, reduction in the rate of visits to the emergency department (ED), and improvements New York Heart Association (NYHA) Functional Classification scores. We also aimed to evaluate the effect of the intervention on HF care-associated costs in terms of cost-effectiveness.

**Methods**

**Design and Setting:**

We conducted a before-and after-intervention trial in chronic HF patients, to evaluate the impact in patient’s outcomes and care associate cost of a new approach for personalize follow-up based on biomarkers risk stratification. It was conducted from the perspective of the Spanish healthcare system in a single academic center (Huelva University Hospital, Huelva, Spain), a 600-bed academic teaching hospital and tertiary care referral center, with all major clinical services. The Heart Failure Unit (HFU) is the referral unit for a population of 550,000 and sees approximately 1000 patients per year. The protocol was approved by the institutional review board, and a waiver of the requirement for a written consent from all participants was approved.

**Participants:**

A total of 192 patients were enrolled between June 2017 to 2018 (figure 1). The study included chronic HF patients, aged 18 years or over and with a reduced left ventricular ejection fraction (LVEF) of 40% or less. In summary, all patients with HF visiting the HFU clinics were consecutively included in the study. Diagnosis and management of HF was in accordance with international guidelines. The follow-up time for all the patients was 12 months before and 12 months after intervention. The follow-up protocol included a medical examination, completion of a patient questionnaire (including all relevant clinical variables, signs and symptoms, medication, NYHA score, use of cardiac resynchronization therapy [CRT] and devices such as...
Implantable cardioverter defibrillators (ICD), blood testing, electrocardiogram (EKG or ECG), and drug treatment adjustments. Before the intervention, all patients were visited every 3 to 6 months according with their symptoms, no matter what their risk was and biomarkers were not used for follow up neither for stratifying risk.

**Intervention:**

We designed a specific intervention based on a personalized follow-up protocol according to a risk stratification score that included biomarkers as first line for risk assess monitoring. At the time of discharge NT-proBNP and high-sensitivity Troponin T (hs-TnT) levels were measured and then, patients were categorized into 3 different groups (low, medium and high risk) according with their risk of readmission calculated using the Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator) [16,17]. BCN Bio-HF Calculator provides with good accuracy (AUC 0.83) the individual risk of hospitalization and all cause-death yearly, up to 5 years in chronic HF patients and incorporates conventional predictors factor as well as NT-proBNP and hs-TnT, that are highly accurate for cardiac malfunction. The calculator was developed with different models allowing its use with different biomarkers. In our study, we used the model that incorporated two biomarkers, NT-proBNP and hs-TnT. According to the risk stratification we developed a personalized follow-up protocol for each group. Quartiles of the total distribution were selected as cut-off points for the different groups, with follow-up at the HFU after discharge as follows:

- Low-risk patients (score <5%), follow-up at 90 days and 12 months.
- Medium-risk patients (score 5–15%), follow-up at 60 days and 6 and 12 months.
- High-risk patients (score >15%), follow-up in 30 days and 3 and 12 months.

**Clinical outcomes:**

The primary outcome compared the rate of readmission post-intervention with pre-intervention, due to a HF event, in the same period between 2017 and 2019.

Secondary outcomes compared the rate of ED visits and the number of patients who had reduced NYHA scores pre- and post-intervention.

**Cost analysis:**

The cost-effectiveness analysis was conducted from the perspective of the Spanish healthcare system, including categories of costs shown in Table 1. All costs were calculated by multiplying the unit cost for the resource use. The average cost of hospitalization was calculated as the number of patients in each NYHA class multiplied by the diagnosis-related group (DRG) cost for each class. The primary care visit unit cost of €78.45 was calculated according to methods used by Merino M et al. [18]. The cost of ED visits was calculated according to the unit cost to the specific DRG of €392.03. The medication unit cost was calculated using the Spanish healthcare prices for Huelva University Hospital in 2018, multiplying by the dose for each patient and calculating the mean in a 1-year period. Laboratory unit costs were calculated as an incremental cost of €14 associated with the cost of the biomarker used during the post-intervention period.
Quality adjusted life-years (QALYs) were calculated by assuming that each functional class has a constant utility function throughout the year, multiplied by 1 year (study period) [17]. The total QALYs were calculated as the sum of each functional class multiplied by the number of patients in that class. All costs were adjusted for inflation to reflect cost related to the year 2018 and excluding indirect costs. For the cost-effectiveness analysis, we considered a temporary analysis of 1 year. To test uncertainty, we used a non-parametric bootstrap method using the original un-transformed data set to generate an empirical distribution for the difference in mean costs, from which we can obtain the confidence interval around the sample mean estimated for costs. The 95% confidence interval for the mean cost in the two groups of patients was obtained non-parametrically using the 5th and 95th percentiles from the distributions as reported in Table 2. We also conducted sensitivity analyses by subgroups. After determining the dominant strategy, we calculated the overall budget impact of using that. This estimation was weighed by the number of HF diagnostic in one year. To assess the budget impact, we simulate three different scenarios: the best case scenario involved that 100% of the HF were managed using the new approach, the intermediate-case scenario involved that 75% of the HF and the worst-case scenario where only 50% of the HF were managed according with the new approach.

**Statistical analysis:**

Sample size was determined based on detecting a difference between groups at 12 months with a power of 80% and a significance level of 5%, detected using a two-tailed t-test, and assuming a loss to follow-up rate of 25%. The rationale for this was based on data from previous studies related to the primary outcome. The sample size required was 143 patients in total, increased to 192 patients due to the expected dropout rate of 25%.

Distributions were examined using the Shapiro–Wilk test to ensure proper statistical evaluation. Continuous variables were expressed as the median with 95% confidence intervals (95% CI), except glomerular filtration, which was expressed as mean ± standard deviation (SD), and the categorical variables, which were expressed as a frequency (percentage, %) of the population. The differences among the categorical variables were analyzed using the chi-square test (χ²), while the Kruskal–Wallis test was used to analyze the differences between independent continuous variables, except glomerular filtration. Significance levels less than 5% were considered significant. Statistical analyses of the data were performed using IBM SPSS software (version 22, SPSS Inc., USA).

**Results**

**Study cohort**

At the time of this analysis, 192 patients had been enrolled in this study with 1 year of follow-up (Figure 1). Table 3 shows the baseline characteristics of the study cohort. Overall, 79.7% of all patients were male, and the mean age (± SD) was 64 ± 12 years. Common comorbidities included hypertension (69.3%), diabetes (37.5%), chronic renal failure (25.8%), chronic obstructive lung disease (20.3%), and atrial fibrillation (34.9%). Of those with heart disease, 50% had coronary artery disease, although a majority of patients (69.8%) had no HF hospitalizations in the year before enrollment. Most patients, 83.7% from Table 3 (NYHA I is 36.1% and NYHA II is 47.6%) were assessed as NYHA Class I or II, reflecting prevalently a mildly symptomatic HF cohort. We found levels of NT-proBNP of 984 [95%CI 393-2334] pg/mL, and hs-TnT levels of 15 [95%CI 8-27] ng/mL. We found
HF hospitalization readmission rates of 30.2% and 21.9% visited the ED during the 12 months prior to the intervention.

The subgroups analysis showed that the patients in the highest risk group were more likely to be older, had more comorbidities, and their heart disease was at a more advanced stage. We found levels of NT-proBNP of 599 [95%CI 244-1211] pg/mL, 2045 [95%CI 860-3664] pg/mL and 3494 [95%CI 1503-8541] pg/mL (p<0.001) and hs-TnT levels of 11 [95%CI 6-16] pg/mL, 24 [95%CI 17-40] pg/mL and 53 [95%CI 39-68] pg/mL (p<0.001) for the low, medium and high risk patients respectively.

For the low risk group 91.4% of the patients were in the lowest functional class (NYHA class I or II), 76.5% for the medium risk group and 50% for the high risk groups. No differences between groups were found in the LVEF either in the use of therapies included Angiotensin-receptor-neprilysin-inhibitor (ARNI), Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB) or beta-blockers (BB).

**Clinical Outcomes**

**Primary outcomes**

Table 3 compares the main outcome of rate of admission 30 days, 6 months and 12 months before and after the intervention, analyzing patients by risk groups. In the cohort of 192 patients, there were 78 admissions for HF (total Length of Stay [LOS] of 647 days) in the 12 months before the intervention. This decreased to 46 admissions after the intervention (total LOS of 295 days), a 41% reduction (p<0.001).

Of the total, 7.8% had been admitted at least once in the 30 days prior to the baseline visit, which reduced to 1% in the 30 days following the intervention (p=0.002). The respective proportions being admitted before and after intervention in the low-, medium- and high-risk groups were 5.1% and 0% (p=NA), 9.5% and 1.6%, (p=0.125), and 25% and 8.3% (p=0.625). Overall, a significant reduction was observed when comparing 6 months before (20.3%) and 6 months after intervention (6.3%) (p<0.001).

Of the 192 patients, 30.2% of the sample had been admitted at least once the previous year; after the intervention, this number decreased to 10.4% in a year (p<0.001). The respective proportions in the low-, medium- and high-risk groups before and after the intervention were: 22.2% and 5.1% (p<0.001); 38.1% and 14.3% (p=0.125); and 66.7% and 41.7% (p=0.453).

**Secondary outcomes**

The rate of visits in the ED also decreased after the intervention (Table 4a). In the 12 months before the study, the number of visits was 64, which decreased to 20 after the intervention, a reduction of 68.8% (p<0.001).

A marked functional improvement was observed after the intervention (Table 4b). In total, 31.1% of the patients improved at least one class in NYHA score, 61.6% remained the same, and 7.3% got worse. The number of asymptomatic patients also increased by 10%.

**Costs analysis**
Table 2 compares the total care associate cost and the specific components during the follow-up between the groups. The overall cost of applying the new follow-up intervention for the cohort of 192 patients was €139,717 lower compared with standard care pre-intervention (Figure 2). We found a significant cost reduction in most of the categories considered. The most important cost reduction was related to costs associated with hospitalization, demonstrating a significant reduction of 78% (p<0.05).

There was a reduction of 69% in the number of ED visits (reduction in total cost for the post-intervention group of €17,249 compared with the pre-intervention group), and there was a significant reduction in the costs associated with primary care visits and with medication. There was a corresponding incremental cost related to the use of biomarkers (€1,728) and HFU visits (€28,567).

Utilizing the personalized biomarker approach produced a total of 113.6 QALYs (95% CI 108.5 to 118.2) compared with 109.1 QALYs (95% CI 104.2 to 113.4) for regular care, an increment of 4.5 QALYs (95% CI 2.9 to 6.1). The new approach was dominant (both less costly and more effective). The sensitivity analysis indicates that the new approach is the most cost-effective decision (Figure 3).

The budget impact analysis showed a potential saving between €-704,028 per 1000 patient-years (p-y) (95% CI 1,141,654 to -273,829) when the saving per patient were translated to the overall patient population in the best-case scenario (100% of the HF patients conducted using our new approach), to €-352,014 p-y (95% CI -570,827 to -136,914) in the worst-case scenario (100% of the HF patients conducted using our new approach), with a medium-case scenario (50% of the HF patients conducted using our new approach) potential saving of €-528,021 (95% CI -856,240 to -205,371). Based on the 80,000 hospital admissions for HF that occur every year in Spain [18], the budget impact, considering only direct costs, could be between €-56,322,308 (95% CI -91,332,342 to -21,906,326) in the best-case scenario and €-28,161,154 (95% CI -45,666,171 to -10,953,163) in the worst-case scenario.

**Discussion**

Although a principal goal of HF management is to improve patient outcomes, few studies have evaluated the possibility of carrying out personalized management to improve them, as we did. The primary finding of this study is that a strategy of personalized follow-up based on cardiac biomarkers for patients with chronic HF and reduced LVEF was more effective than regular care in reducing the composite outcome of readmission rates. Significantly different results were seen in other clinical outcomes, including a reduction of ED visits and improvement in patients’ NYHA classification during the monitoring period. There was also a significant reduction in the HF-associated cost using the personalized approach compared with the strategy used in regular care.

These results are comparable with the published literature; the 1-year incidence rate of readmission was reported at 14.5% among 12,440 chronic HF patients from different geographical areas [6]. A systematic review of different strategies for HF management found 6/19 trials demonstrated statistically significant reductions in HF readmissions with multidisciplinary management and personalized follow-up strategies [19]. The average reduction in readmission rates was 12.37% over 12 months’ follow-up, varying between 2.71% and 17.81% [19,20]; differences between types of interventions were not found.
Although difficult to compare across studies, the reduction in hospitalization readmissions after 1 year of follow-up was substantially higher in this study (17–25% across risk groups). This may result from the focusing of resources on those patients at highest risk. We believe this study is the first to propose a personalized follow-up procedure based on the patient’s risk, assessed in a real-world clinical scenario, and suggests that greater attention should be given to the high-risk cohort to minimize the risk of readmissions; given that most hospital readmissions are for non-HF reasons, a comprehensive medical treatment plan has been implemented.

As many as 77% of high-risk patients initially present to the ED [22], and close follow-up after discharge has been shown to decrease ED admissions [23,24]. Our results differ from these studies and show a significant reduction of 68.7% in ED admissions during the follow-up period. Although the majority of hospitalizations for HF begin in the ED, close outpatient follow-up and management has been proposed as a viable strategy to reduce readmissions.

We found a reduction in the percentage of patients in NYHA class III and an increasing number of patients in NYHA class I and II at follow-up, comparable with the results of Romano et al. ED [25] and other authors that found a significant improve in NYHA class after different interventions in patients with HFrEF [26]. NYHA class is recommended in all guidelines as a useful tool to assess the functional limitations imposed on a patient by their heart failure. In fact, NYHA functional class was the most dominant predictor among several somatic variables studied, without LVEF or duration of HF associated with a decrease in quality of life [27]. The results of the current study strongly support the current guidelines regarding NYHA class reduction as primary endpoint for therapeutically interventions in HF.

Our cost analysis results agree with those proposed by other groups; Lesyuk et al. [28] found that 44–96% of the direct costs of HF care are due to hospitalization, suggesting that reduction of readmission rates would reduce the direct cost associated with HF. Our study also reports a significant reduction in the cost related to emergency admission and primary care visits, which we believe are associated with better control of the patients after the intervention. The significant reduction in NYHA class could also contribute to the cost reduction; patients with NYHA IV have between 8 and 30 times higher healthcare costs than patients with NYHA II [29,30].

Data for the cost-effectiveness of biomarker-guided personalized outpatient management of HF patients are limited. Our cost-effective analysis showed that personalized follow-up was the dominant approach, with a potential saving of €-704,028.85 per 1000 p-y. Given the expected cost differential between serial biomarker monitoring and hospitalization for HF, even a modest reduction in admissions due to biomarker personalized follow-up could result in net cost savings. Biomarker personalized therapy has a high probability of being cost-effective in HF patients with reduced LVEF [30].

This study has several limitations. The data needs to be validated in a multicenter, randomized clinical trial. The model of care for HF is currently carried out according to local practices, where there is a large variability in the clinical management of patients. Our study only reflects the experience of a single hospital, and the analyses were conducted from the Spanish health system perspective, including pricing. General population data ranges were used in the sensitivity analyses to improve generalizability. Demonstrating the prices and
efficacy necessary for cost-effectiveness at each threshold makes our results relevant to other systems, and transferrable to clinical practice.

**Conclusions**

In conclusion, personalized handling in HF, with novel clinical strategies for optimizing treatment, improving outcomes, and reducing the cost in HF, is sorely needed. Our strategy of personalized follow-up based on cardiac biomarkers to optimize HF management represents a major new approach to achieve these goals.

**Abbreviations**

HF Heart Failure

HFrEF heart failure with reduced-ejection-fraction

ICHOM International Consortium for Health Outcomes Measurement

ED Emergency department

NYHA New York Heart Association

HFU Heart Failure Unit

LVEF left ventricular ejection fraction

CRT cardiac resynchronization therapy

ICD implantable cardioverter defibrillator

ECK/ECG electrocardiogram

NT-proBNP N-terminal pro b-type natriuretic peptide

Hs-TnT Troponin T

BCN Bio-HF Calculator Barcelona Bio-Heart Failure Risk Calculator

AUC Area under the ROC Curve

DRG Diagnosis-related group

QALYs Quality adjusted life-years

CI Confidence intervals

SD standard deviation

ARNI Angiotensin-receptor-neprilysin-inhibitor
ACIE Angiotensin Converting Enzyme Inhibitor

ARB Angiotensin Receptor Blocker

BB Beta-blockers

**Declarations**

**Ethics approval and consent to participate**

The study is in accordance with Helsinki Declaration. Institutional ethics committee approval was obtained from the Huelva University Hospital, Research Ethics Committee. Participants gave their informed consent.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

JMG reports personal fees from Roche Diagnostics International Ltd during the conduct of the study. All other authors have nothing to disclose.

**Funding**

None declared.

**Authors' contributions**

All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Acknowledgements**

None declared.

**References**

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-1146. doi:10.1136/hrt.2003.025270.
2. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Blaha MJ, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399-410. doi:10.1161/01.cir.0000442015.53336.12.

4. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-817. doi:10.1093/eurjhf/hft050.

5. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26(6):447-62. doi: 10.2165/00019053-200826060-00001. PMID: 18489197.

6. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions [published correction appears in Eur J Heart Fail. 2017 Mar;19(3):438]. Eur J Heart Fail. 2016;18(6):613-625. doi:10.1002/ejhf.566.

7. Albert NM, Barnason S, Deswal A, Hernandez A, Kociol R, Lee E, et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. Circ Heart Fail. 2015;8(2):384-409. doi:10.1161/HHF.0000000000000006.

8. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program [published correction appears in N Engl J Med. 2011 Apr 21;364(16):1582]. N Engl J Med. 2009;360(14):1418-1428. doi:10.1056/NEJMa0803563.

9. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent?. Circulation. 2012;126(4):501-506. doi:10.1161/CIRCULATIONAHA.112.125435.

10. Ahmad FA, Petrie MC, McMurray JJV, Lang NN. Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. Eur J Heart Fail. 2019;21(6):699-702. doi:10.1002/ejhf.1463.

11. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J. 2016 Dec 30;:]. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128.

12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803. doi:10.1016/j.jacc.2017.04.025.

13. Angermann CE, Gelbrich G, Störk S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. 2016;315(24):2683–2693. doi:10.1010/jama.2016.7635.

14. Gallagher AM, Lucas R, Cowie MR. Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach. ESC Heart Fail. 2019 Feb;6(1):3-9. doi: 10.1002/ehf2.12363. Epub 2018 Oct 11. PMID: 30311454; PMCID: PMC6352889.

15. M. O’Connor, Better Quality of Life Over More Quantity of Life: How We View Time Trade-Off, JACC Hear. Fail. 7 (2019) 531–532. https://doi.org/10.1016/j.jchf.2019.05.001.
16. Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, et al. Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One. 2014;9(1):e85466. Published 2014 Jan 15. doi:10.1371/journal.pone.0085466.

17. Lupón J, Januzzi JL, de Antonio M, Vila J, Peñafiel J, Bayes-Genis A. Validation of the Barcelona Bio-Heart Failure Risk Calculator in a cohort from Boston. Revista Espanola de Cardiologia (English ed.). 2015 Jan;68(1):80-81. DOI: 10.1016/j.rec.2014.08.009.

18. Merino M, Jiménez M, Manito N, et al. The social return on investment of a new approach to heart failure in the Spanish National Health System. ESC Heart Failure. 2020 Feb;7(1):130-137. DOI: 10.1002/ehf2.12535.

19. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44(4):810-819. doi:10.1016/j.jacc.2004.05.055.

20. Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA, et al. Randomized, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. Eur Heart J. 2002;23(2):139-146. doi:10.1053/euhj.2001.2712.

21. Blue L, Lang E, McMurray JJ et al. Randomised controlled trial of specialist nurse 405 intervention in heart failure. BMJ (Clinical research ed) 2001;323:715-8.

22. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209-216. doi:10.1016/j.ahj.2004.08.005.

23. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation. 2010;122(19):1975-1996. doi:10.1161/CIR.0b013e3181f9a223.

24. Blecker S, Ladapo JA, Doran KM, Goldfeld KS, Katz S. Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. Am Heart J. 2014;168(6):901-8.e1. doi:10.1016/j.ahj.2014.08.002.

25. Romano G, Vitale G, Ajello L, Agnese V, Bellavia D, Caccamo G, et al. The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The "Hemodynamic Recovery". J Clin Med. 2019;8(12):2165. Published 2019 Dec 6. doi:10.3390/jcm8122165.

26. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019 Jul 2;8(13):e012272. doi: 10.1161/JAHA.119.012272. Epub 2019 Jun 26. PMID: 31240976; PMCID: PMC6662364.

27. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002 Mar;87(3):235-41. doi: 10.1136/heart.87.3.235. PMID: 11847161; PMCID: PMC1767036.
28. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord. 2018;18(1):74. Published 2018 May 2. doi:10.1186/s12872-018-0815-3.

29. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3(3):283-291. doi:10.1016/s1388-9842(01)00123-4.

30. Sanders-van Wijk S, van Asselt AD, Rickli H et al. Cost-effectiveness of N461 terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: 462 results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in 463 Elderly Patients with Congestive Heart Failure). JACC Heart failure 2013;1:64-71.

Tables

Table 1: Categories of costs included in the analysis, per unit

| Category                        | Cost (€)  |
|---------------------------------|-----------|
| **Hospitalization cost**        | 3,981.89  |
| NYHA 1                          | 2,900.76  |
| NYHA 2                          | 3,654.64  |
| NYHA 3                          | 4,426.22  |
| NYHA 4                          | 6,662.33  |
| **Primary care visits**         | 78.45     |
| **Emergency Department visits** | 392.03    |
| **Heart Failure Unit visits**   | 97.83     |
| **Medication cost**             | 1.32      |
| ACEI                            | 0.09      |
| ARA II                          | 0.54      |
| MRA                             | 0.04      |
| Ivabradine                      | 0.36      |
| Diuretics                       | 0.03      |
| Statins                         | 0.13      |
| Angiotensin receptor-neprilysin inhibitors | 0.54 |
| **Biomarkers cost**             | 14.00     |
| NT-proBNP (pg/mL)               | 12.00     |
| hs T-Troponin (ng/mL)           | 2.00      |
ACEI, Angiotensin-converting enzyme inhibitor; ARA, aldosterone receptor antagonist; MRA, Mineralocorticoid receptor antagonist; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-brain natriuretic peptide

Table 2: Differences in total costs during the 12 months of follow-up for the pre-intervention and post-intervention groups by individual cost categories

| Cost Categories                | Pre-intervention (€, 95% CI) | Post-intervention (€, 95% CI) | Difference (€, 95% CI) |
|-------------------------------|------------------------------|------------------------------|------------------------|
| Hospitalization cost          | 276,240.59 [196,934.82, 376,573.91] | 128,188.07 [60,774.36, 217,678.26] | -148,052.52 [-237,083.74, -63,958.01] |
| Primary Care Visits           | 4,550.10 [3,136.04, 6,276.00] | 1,804.35 [941.40, 3,059.55] | -2,745.75 [-4,785.45, -1,019.85] |
| Emergency Department Visits   | 25,089.92 [16,465.26, 36,860.62] | 7,840.60 [4,312.33, 12,152.93] | -17,249.32 [-29,794.28, -1,019.85] |
| Heart Failure Unit Visits     | 54,195.65 [52,120.64, 55,983.00] | 82,762.83 [80,013.51, 85,954.66] | 28,567.18 [23,680.63, 33,374.36] |
| Medication cost               | 26,207.00 [23,698.17, 28,864.29] | 25,969.75 [23,622.44, 28,449.38] | -237.25 [-1,909.68, 1,335.90] |
| Total                         | 386,283.26 [303,583.75, 487,853.96] | 246,565.60 [177,569.86, 338,841.40] | -139,717.65 [-224,000.78, -63,958.01] |

Table 3: Baseline characteristics of the study cohort, for associations between variables depending on the score groups
|                                | Total (N=192) | Low-risk (n=117) | Medium-risk (n=63) | High-risk (n=12) | p value |
|--------------------------------|--------------|------------------|-------------------|-----------------|---------|
| **Age (years)**                | 65 [57–73]   | 60 [53–69]       | 72 [66–77]        | 73 [65–81]      | <0.001  |
| **Gender (female)**            | 20.3         | 23.9             | 14.3              | 16.7            | 0.292   |
| **Arterial hypertension**      | 69.3         | 58.1             | 85.7              | 91.7            | <0.001  |
| **Dyslipidemia**               | 64.1         | 52.1             | 82.5              | 83.3            | <0.001  |
| **Diabetes mellitus**          | 37.5         | 25.6             | 54.0              | 66.7            | <0.001  |
| **COPD**                       | 20.3         | 13.7             | 30.2              | 33.3            | 0.016   |
| **Chronic renal failure**      | 25.8         | 13.0             | 42.9              | 58.3            | <0.001  |
| **Previous atrial fibrillation** | 34.9      | 22.2             | 50.8              | 75.0            | <0.001  |
| **LVEF**                       | 30 [27–36]   | 30 [28–36]       | 30 [28–36]        | 27 [25–32]      | 0.116   |
| **Ischemic etiology**          | 50           | 40.2             | 65.1              | 66.7            | 0.003   |
| **Functional class**           |              |                  |                   |                 |         |
| NYHA 1                         | 36.1         | 44.8             | 23.8              | 16.7            |         |
| NYHA 2                         | 47.6         | 46.6             | 52.4              | 33.3            | <0.001  |
| NYHA 3                         | 16.2         | 8.6              | 23.8              | 50.0            |         |
| **ICD/CRT**                    | 12.0         | 5.1              | 20.6              | 33.3            | 0.001   |
| **Heart rate**                 | 61 [55-70]   | 60 [55-66]       | 63 [60-70]        | 64 [59-80]      | 0.107   |
| **NT-proBNP (pg/mL)**          | 984          | 599              | 2045              | 3494            | <0.001  |
|                               | [393–2334]   | [244–1211]       | [860–3664]        | [1503–8541]     |         |
| **hs T-Troponin (ng/mL)**      | 15 [8–27]    | 11 [6–16]        | 24 [17–40]        | 53 [39–68]      | <0.001  |
| **Glomerular filtration**      | 76.07±27.75  | 86.36±23.66      | 62.54±22.59       | 46.75±38.50     | <0.001  |
| (mL/min/1.73 m²)               |              |                  |                   |                 |         |
| **Sodium (mEq/L)**             | 141 [140–143]| 141 [140–143]    | 142 [141–144]     | 139 [138–141]   | 0.005   |
| **ACEI/ARB**                   | 60.4         | 62.4             | 58.7              | 50.0            | 0.667   |
| **ARNI**                       | 38.0         | 35.9             | 39.7              | 50.0            | 0.598   |
| **Betablockers**               | 95.8         | 97.4             | 95.2              | 83.3            | 0.064   |
| **MRA**                        | 78.1         | 76.1             | 82.5              | 75.0            | 0.584   |
Diuretics  

|                | 67.7 | 47.0 | 100.0 | 100.0 | <0.001 |
|----------------|------|------|-------|-------|--------|

Data are presented as median [95% CI] for continuous variables and percentages for categorical variables.

ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; ICT, implantable cardioverter debrillators; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-brain natriuretic peptide

Table 4: Rehospitalization rates, rate of admission from the emergency department (ED), and NYHA functional classification scores, 30 days, 6 months and 12 months pre- and post-intervention

| Sample size | Pre-intervention | Post-intervention | p value |
|-------------|------------------|-------------------|---------|
| 30-days admissions (%) | | | |
| All (N=192) | 7.8 | 1 | 0.002 |
| Low risk (n=117) | 5.1 | 0 | NA |
| Medium risk (n=63) | 9.5 | 1.6 | 0.125 |
| High risk (n=12) | 25 | 8.3 | 0.625 |
| 6-months admissions (%) | | | |
| All (N=192) | 20.3 | 6.3 | <0.001 |
| Low risk (n=117) | 15.4 | 1.7 | <0.001 |
| Medium risk (n=63) | 23.8 | 11.1 | 0.096 |
| High risk (n=12) | 50 | 25 | 0.453 |
| 12-months admissions (%) | | | |
| All (N=192) | 30.2 | 10.4 | <0.001 |
| Low risk (n=117) | 22.2 | 5.1 | <0.001 |
| Medium risk (n=63) | 38.1 | 14.3 | 0.003 |
| High risk (n=12) | 66.7 | 41.7 | 0.453 |

Table 5.a Change in ED visits pre- and post-intervention (total and by subgroups)
|                        | Pre-intervention | Post-intervention | p value |
|------------------------|------------------|-------------------|---------|
| **30-day ED visits (%)** |                  |                   |         |
| Total (N=192)          | 4.7              | 0                 | NA      |
| Low risk group (n=117) | 1.7              | 0                 | NA      |
| Medium risk group (n=63)| 7.9              | 0                 | NA      |
| High risk group (n=12) | 16.7             | 0                 | NA      |
| **6-months ED visits (%)** |                  |                   |         |
| Total (N=192)          | 12.5             | 2.1               | <0.001  |
| Low risk group (n=117) | 7.7              | 0.9               | 0.021   |
| Medium risk group (n=63)| 15.9             | 1.6               | 0.012   |
| High risk group (n=12) | 41.7             | 16.7              | 0.375   |
| **12-months ED visits (%)** |                  |                   |         |
| Total (N=192)          | 21.9             | 7.3               | <0.001  |
| Low risk group (n=117) | 12.8             | 3.4               | 0.013   |
| Medium risk group (n=63)| 31.7             | 9.5               | 0.007   |
| High risk group (n=12) | 58.3             | 33.3              | 0.453   |

Table 5.b Change in functional class (NYHA) pre- and post-intervention (total and by subgroups)

|                  | Improved (%), 95% CI | No change (%), 95% CI | Worse (%), 95% CI |
|------------------|----------------------|-----------------------|------------------|
| **Total**        | 31.07 (24.71, 37.78) | 61.58 (54.94%, 67.86) | 7.34 (3.87, 11.3) |
| **Low**          | 28.70 (20.72, 37.28) | 65.74 (56.91, 73.69)  | 5.56 (1.9, 10.48) |
| **Medium**       | 37.93 (26.15, 50)    | 53.45 (41.43, 65.08)  | 8.62 (1.75, 16.67) |
| **High**         | 22.22% (0, 55.6)     | 55.56 (20, 90)        | 22.22 (0, 50)     |

*Confidence intervals were calculated with n = 1000 and 95% confidence level.*